Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.68 |
| ▸ | RAB9A | P51151 | 3/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.68 |
| ▸ | MAPT | P10636 | 3/20 | 0.68 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.68 |
| ▸ | HTT | P42858 | 2/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.68 |
| ▸ | MEN1 | O00255 | 1/20 | 0.68 |
| ▸ | XBP1 | P17861 | 1/20 | 0.68 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.66 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.66 |
| ▸ | TRPV1 | Q8NER1 | 4/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | KIF11 | P52732 | 1/20 | 0.58 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.57 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.56 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.56 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.56 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.56 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11767622 | 0.90 | NPC1 (0.57) | NPC1RAB9ASMN1; SMN2MAPTMAPK1 | |
| SCHEMBL2730172 | 0.90 | MAPT (0.81) | NPC1RAB9ASMN1; SMN2MAPTMAPK1 | |
| SCHEMBL13756246 | 0.90 | MAPT (0.81) | NPC1RAB9ASMN1; SMN2MAPTMAPK1 | |
| SCHEMBL10155599 | 0.85 | ALDH1A1 (0.78) | NPC1RAB9ASMN1; SMN2MAPTKMT2A | |
| SCHEMBL12585027 | 0.82 | MAPT (0.71) | NPC1RAB9ASMN1; SMN2MAPTMAPK1 | |
| SCHEMBL17072026 | 0.82 | EPHX2 (0.74) | NPC1RAB9ASMN1; SMN2MAPTMAPK1 | |
| SCHEMBL13141239 | 0.82 | NPC1 (0.68) | NPC1RAB9ASMN1; SMN2MAPTMAPK1 | |
| SCHEMBL9037064 | 0.82 | NPC1 (0.66) | NPC1RAB9ASMN1; SMN2MAPTMAPK1 | |
| SCHEMBL12413880 | 0.82 | EPHX2 (0.78) | NPC1RAB9AMAPTHTTKMT2A | |
| SCHEMBL20458866 | 0.82 | ALDH1A1 (0.53) | NPC1RAB9ASMN1; SMN2MAPTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239764-A1 | SUBSTITUTED AMINOBENZYL HETEROARYL COMPOUNDS AS EGFR AND/OR PI3K INHIBITORS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2024-07-18 | — | — | US | disclosed |
| US-11649214-B2 | Inhibitors of the notch transcriptional activation complex kinase (“NACK”) and methods for use of the same | UNIVERSITY OF MIAMI (US) | 2023-05-16 | — | — | US | disclosed |
| US-11649214-B2 | Inhibitors of the notch transcriptional activation complex kinase (“NACK”) and methods for use of the same | UNIVERSITY OF MIAMI (US) | 2023-05-16 | — | — | US | disclosed |
| US-20210171469-A1 | INHIBITORS OF THE NOTCH TRANSCRIPTIONAL ACTIVATION COMPLEX KINASE (\"NACK\") AND METHODS FOR USE OF THE SAME | UNIVERSITY OF MIAMI | 2021-06-10 | — | — | US | disclosed |
| US-10842791-B2 | Small molecule inhibitors of EGFR and PI3K | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2020-11-24 | — | — | US | disclosed |
| US-10640462-B2 | Oil gelator | NATIONAL UNIVERSITY CORPORATION SHIZUOKA UNIVERSITY (JP) | 2020-05-05 | — | — | US | disclosed |
| EP-3381995-B1 | OIL-GELLING AGENT | UNIV SHIZUOKA NAT UNIV CORP (JP) | 2019-10-23 | — | — | EP | disclosed |
| US-20190167686-A1 | SMALL MOLECULE INHIBITORS OF EGFR AND PI3K | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2019-06-06 | — | — | US | disclosed |
| EP-2629771-B1 | USE OF PI3K INHIBITORS FOR THE TREATMENT OF OBESITY, STEATOSIS AND AGEING | FUNDACION CENTRO NAC DE INVESTIGACIONES ONCOLOGICAS CARLOS III (ES) | 2018-08-08 | — | — | EP | disclosed |
| US-9993554-B2 | Use of P13K Inhibitors for the Treatment of Obesity, Steatosis and ageing | CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO) (ES) | 2018-06-12 | — | — | US | disclosed |
| US-20150284422-A1 | INHIBITORS OF PROTEIN METHYLTRANSFERASE DOT1L AND METHODS OF USE THEREOF | Epizyme, Inc. | 2015-10-08 | — | — | US | disclosed |
| WO-2015013256-A1 | NON-RIBOSE CONTAINING INHIBITORS OF HISTONE METHYLTRANSFERASE DOT1L FOR CANCER TREATMENT | BAYLOR COLLEGE OF MEDICINE (US) | 2015-01-29 | — | — | WO | disclosed |
| WO-2014153001-A1 | COMBINATION THERAPY FOR TREATING CANCER | Epizyme, Inc. (US) | 2014-09-25 | — | — | WO | disclosed |
| US-8778935-B2 | Imidazopyrazines for use as kinase inhibitors | CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO) (ES) | 2014-07-15 | — | — | US | disclosed |
| WO-2014100662-A1 | DOT1 L INHIBITORS FOR USE IN THE TREATMENT OF LEUKEMIA | Epizyme, Inc. (US) | 2014-06-26 | — | — | WO | disclosed |
| US-20140154232-A1 | Use of Pl3K Inhibitors for the Treatment of Obesity, Steatosis and Ageing | CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO) (ES) | 2014-06-05 | — | — | US | disclosed |
| WO-2014026198-A1 | INHIBITORS OF PROTEIN METHYLTRANSFERASE DOT1L AND METHODS OF USE THEREOF | Epizyme, Inc. (US) | 2014-02-13 | — | — | WO | disclosed |
| US-8637561-B2 | Linked diimidazole derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2014-01-28 | — | — | US | disclosed |
| US-20130029967-A1 | Fused Imidazo [3,2 - D] Pyrazines as P13 Kinase Inhibitors | CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO) (ES) | 2013-01-31 | — | — | US | disclosed |
| US-20120083492-A1 | IMIDAZOPYRAZINES FOR USE AS KINASE INHIBITORS | CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO) (ES) | 2012-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150284422-A1 | INHIBITORS OF PROTEIN METHYLTRANSFERASE DOT1L AND METHODS OF USE THEREOF | DOT1L, PRMT1, CARM1 | NPC1 1594/4885RAB9A 2637/4885SMN1; SMN2 1240/4885 |
| US-20140154232-A1 | Use of Pl3K Inhibitors for the Treatment of Obesity, Steatosis and Ageing | PLIN1, PCK2, PLIN3 | NPC1 2475/4885RAB9A 2832/4885SMN1; SMN2 4588/4885 |
| US-20130029967-A1 | Fused Imidazo [3,2 - D] Pyrazines as P13 Kinase Inhibitors | MTOR, PIK3CA, CDK2 | NPC1 1827/4885RAB9A 1048/4885SMN1; SMN2 2921/4885 |
| US-10640462-B2 | Oil gelator | MGLL, CCNL2, CCNI | NPC1 1844/4885RAB9A 3745/4885SMN1; SMN2 3638/4885 |
| US-20240239764-A1 | SUBSTITUTED AMINOBENZYL HETEROARYL COMPOUNDS AS EGFR AND/OR PI3K INHIBITORS | EGFR, ERBB2, ERBB3 | NPC1 1866/4885RAB9A 193/4885SMN1; SMN2 4073/4885 |
| US-20210171469-A1 | INHIBITORS OF THE NOTCH TRANSCRIPTIONAL ACTIVATION COMPLEX KINASE (\"NACK\") AND METHODS FOR USE OF THE SAME | CHUK, NOTCH1, NUAK1 | NPC1 1675/4885RAB9A 3204/4885SMN1; SMN2 4761/4885 |
| US-20120083492-A1 | IMIDAZOPYRAZINES FOR USE AS KINASE INHIBITORS | MTOR, PIK3CA, PI4KA | NPC1 1225/4885RAB9A 1302/4885SMN1; SMN2 3221/4885 |
| US-10842791-B2 | Small molecule inhibitors of EGFR and PI3K | EGFR, ERBB2, ERBB3 | NPC1 2896/4885RAB9A 546/4885SMN1; SMN2 4865/4885 |
| US-20190167686-A1 | SMALL MOLECULE INHIBITORS OF EGFR AND PI3K | EGFR, ERBB2, ERBB3 | NPC1 2896/4885RAB9A 546/4885SMN1; SMN2 4865/4885 |
| US-11649214-B2 | Inhibitors of the notch transcriptional activation complex kinase (“NACK”) and methods for use of the same | NOTCH1, CHUK, CBFB | NPC1 1607/4885RAB9A 3062/4885SMN1; SMN2 4745/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.